ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed 08 December 8:00AM
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
42.20
Bid
41.80
Offer
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
Gmenfan Gmenfan 1 minute ago
https://media.gettr.com/group5/getter/2024/12/05/16/8889bd5b-cd83-04d0-5dad-ffeed3d3764f/3b33684d2074b2b0f347f9bc73b37a7f_768x0.png
jammy32 jammy32 2 minutes ago
PLUG needs to look at posts about the,
PLUG
janice shell janice shell 2 minutes ago
It's indifference. When my ex was having health issues and was denied medicine that her doctor prescribed to her, I went ballistic. She got healthy and I still hold the bill.

It's not "indifference". It's greed. Many people at the insurance companies don't care whether their patients
Livi1 Livi1 2 minutes ago
The wick has been lit. $RDAR
RDAR
$Gambler $Gambler 2 minutes ago
Only 20 for a high here today, will be cool tonight.
CGAC
Alley-oop Alley-oop 3 minutes ago
Ybyrá Capital (YBRA4) is a publicly traded Brazilian investment holding company with
more than 26 years of experience and has more than one billion dollars under management.
style
HMBL
Gmenfan Gmenfan 3 minutes ago
Outstanding!!
thehawk72 thehawk72 3 minutes ago
I think coerced is too harsh for what both parties are arguing. Misrepresentations are concerning to the court... the way I read this.
WDLF
yielddude yielddude 4 minutes ago
26 stocks with a 90%+ return. Wow.
1vman 1vman 5 minutes ago
*****LMAO !!! 🚽DBMM🚽 SEC says 80 bucks possible here ? where's the link to dat ? - just more Stinky OTC pinky nonsense dreamed up by conspiracy theorists - Wh👀ps

https://investorshub.advfn.com/uimage/uploads/2024/2/20/igejjgiphy.webp


ENOU
DBMM
 just Scottie just Scottie 6 minutes ago
No choice for me! Yes thanks same to you!
GEGI
BDEZ BDEZ 6 minutes ago
I never realized they could connect with each other.
Gmenfan Gmenfan 6 minutes ago
That would be spectacular but sadly we know the deep state would never allow that to happen.
1vman 1vman 6 minutes ago
*****🟥🟥🟥 LOL ! Theres no share buyback here !!! let alone 5 million - Wh👀ps

First the nonsense was 1 billion buy back no its 5 million

https://investorshub.advfn.com/uimage/uploads/2024/9/12/ypv[ilaughing-baby.gif

ENOUGH SA
HCMC
back2basics back2basics 7 minutes ago
YEA Israel||||

B2B
chen1992 chen1992 7 minutes ago
And you’re a waste of space your momma should have swallowed you but didn’t. You have no friends in real life. A loner both here and in real life.
TGLO
Bobbar Bobbar 8 minutes ago
Hopefully we get current and than start releasing PRs and we will be on a roll

Not just short term but long term also
UATG
Golden Cross Golden Cross 8 minutes ago
~ $ILLR Positioned in a $180B Creator Economy, Triller Group harnesses AI and machine learning to optimize content for mobile and TV audiences. We’re bridging creator-driven media with innovative tech solutions.
https://x.com/triller_IR/status/1853421942260265451
ILLR
jimr1717 jimr1717 9 minutes ago
Can you please have someone read the filing for you.

There might be some but there are not many that are Fooled by the CONdog96 🤡™
Clown.

“ which may cause the market for our shares to decrease.”
ATMH
back2basics back2basics 9 minutes ago
I agree completely|||

Trump is the Rhino that will trample the RINOS.

B2B
StayHumble StayHumble 9 minutes ago
🎃wow✅Win-Win $UBQU erases $2Million💹of debt in 12months✅

https://www.otcmarkets.com/stock/UBQU/news/EQS-News-Ubiquitech-Software-Corp-OTCUBQU-Successfully-Eliminates-Additional-Convertible-Debt-Bringing-Recent-Total-Elim?id=444198
UBQU
MeteoricChimera43 MeteoricChimera43 10 minutes ago
Ahhhhhhh. We hurt his feelings. 😂😂. The fact is DAXXIFY has value and cannot be replicated without years of R&D and close to a billion dolllars. Thats what we’re investing in, not Foley. Don’t go away mad pal, just go away
RVNC
stockinspector stockinspector 10 minutes ago
The article is written as if Co. guys are bad and the 95 decisions to buy were coerced.
But that is how lawyers and judges buy sports cars so we will have to see.

WDLF
lakers17 lakers17 10 minutes ago
Memes running today a little. PEPE to .000025

Your Recent History

Delayed Upgrade Clock